Screening Utility of Lower Limb Muscle Ultrasound for Sarcopenia in COPD Patients Authors: Jing Huang, Fei Guo, Li Jiang, Jierong Quan, Lu Yu, Xiao Nie, Huaicong Long Published: 2026 ABSTRACT AbstractPurposeSarcopenia is a common but underdiagnosed extrapulmonary complication in patients with chronic obstructive pulmonary disease (COPD) and contributes to poor clinical outcomes. This study aimed to investigate the screening utility of rectus femoris cross-sectional area (RFCSA), femoral muscle thickness (FMT), and quadriceps femoris muscle thickness (QFMT) for sarcopenia in COPD patients.Patients and MethodsThis single-center cross-sectional study enrolled 61 COPD patients. According to the sarcopenia criteria, patients were classified into sarcopenia group (n=24) and non-sarcopenia group (n=37). All participants underwent pulmonary function tests, grip strength measurement, 6-meter walk test, 5-repetition sit-to-stand test, and bioelectrical impedance analysis. QFMT, FMT, and RFCSA were measured by a single experienced sonographer using a standardized protocol. Multivariable logistic regression and receiver operating characteristic (ROC) curve analysis were performed.ResultsThe proportion of participants with sarcopenia in this COPD cohort was 39.34% (24/61). All ultrasound parameters were significantly reduced in the sarcopenia group: QFMT (2.28 cm vs 2.57 cm, p<0.001), FMT (1.30±0.21 cm vs 1.43±0.23 cm, p=0.033), and RFCSA (4.25±0.75 cm2 vs 4.72±0.75 cm2, p=0.019). Multivariable logistic regression adjusting for age, sex, BMI, and FEV1% pred confirmed QFMT as an independent factor of sarcopenia (OR=0.121, 95% CI: 0.021–0.697, p=0.018). ROC analysis revealed that QFMT had the highest AUC among single parameters (AUC=0.767, 95% CI: 0.642–0.866). At the optimal cut-off of 2.833 cm, QFMT showed a sensitivity of 100% and specificity of 43.24%. When QFMT, FMT, and RFCSA were combined, the AUC was 0.777 (95% CI: 0.652–0.874), with a sensitivity of 50% and specificity of 94.59%, representing only a marginal improvement over QFMT alone (p=0.711 by DeLong test).ConclusionLower limb muscle ultrasound parameters, particularly QFMT, are significantly reduced in COPD patients with sarcopenia. Ultrasound appears promising as a screening tool but requires validation in larger, prospective, multicenter studies.Keywords: chronic obstructive pulmonary disease, ultrasound, quadriceps femoris muscle, rectus femoris, sarcopenia screening Introduction Chronic obstructive pulmonary disease (COPD) is a common respiratory disorder with significant morbidity and mortality.1 The high mortality of COPD imposes substantial economic and health burdens on healthcare systems, underscoring the importance of comprehensive disease management. Studies have confirmed that COPD frequently coexists with various extrapulmonary diseases, including sarcopenia, osteoporosis, cor pulmonale, and metabolic syndrome, which complicate patient management and worsen prognosis.2–4 Among them, the overall prevalence of sarcopenia in COPD patients is approximately 29%, and age is an important risk factor for COPD with sarcopenia.5 Sarcopenia in COPD is not merely an age-related disorder.6 Emerging evidence indicates that chronic systemic inflammation, oxidative stress, physical inactivity, and corticosteroid exposure play pivotal roles in the pathogenesis of muscle wasting in COPD.6,7 These factors create a vicious cycle: muscle dysfunction leads to reduced physical activity, which in turn exacerbates muscle atrophy and systemic inflammation.6 Sarcopenia is a syndrome characterized by progressive and generalized loss of skeletal muscle mass, muscle strength, and physical function.8 The clinical symptoms of COPD patients with sarcopenia are more complex, which increases the difficulty of the management of COPD patients and seriously affects the efficacy of COPD treatment.4 Therefore, early identification of COPD patients with sarcopenia may optimize the comprehensive management of COPD, improve the therapeutic efficacy. Currently, there is no consensus on the diagnostic criteria for sarcopenia in the world. However, both the Asian Working Group for Sarcopenia (AWGS) and the European Working Group for Sarcopenia have unified muscle mass, physical function and muscle strength as the core parts of the diagnosis of sarcopenia.8,9 Among them, the decline of muscle mass is an important criterion for the identification of sarcopenia. The assessment of muscle mass requires specialized equipment, including dual-energy X-ray absorptiometry (DXA), magnetic resonance imaging (MRI), computed tomography (CT). DXA, CT, and MRI are rarely used in routine clinical practice due to their high cost, limited availability, and radiation exposure (in the case of CT). Owing to its cost-effectiveness and portability, ultrasound (US) has attracted increasing attention as a promising tool for sarcopenia assessment in recent years.10,11 Participants with COPD or during acute exacerbations may experience more significant loss of muscle mass and strength in the lower limbs.11,12 Muscle dysfunction is also more pronounced in the lower than in the upper extremities, which compromises ambulatory capacity and adversely affects daily life.13 The rectus femoris and quadriceps femoris are key muscles for gait and mobility; their superficial anatomical location makes them readily accessible for point-of-care US assessment. Previous studies have shown that US of the lower limbs demonstrates screening potential for sarcopenia.14,15 However, there are relatively few studies in COPD patients. The aim of this study was to investigate the screening utility of rectus femoris cross sectional area (RFCSA), femoral muscle thickness (FMT), and quadriceps femoris muscle thickness (QFMT) for sarcopenia in COPD patients. Materials and Methods Study Population This was an exploratory cross-sectional study; no a priori sample size calculation was performed. The study flow diagram is presented in Figure 1. The study included a total of 86 consecutive eligible COPD patients who were recruited from the Pulmonary Function Laboratory and Respiratory Medicine Department of the Sichuan Provincial People’s Hospital. Data were collected between September 2021 and November 2022. The number of participants was limited by the study period and the availability of eligible COPD patients. The final sample comprised 61 participants. All procedures were performed in accordance with the ethical standards of the institution and the principles outlined in the Declaration of Helsinki. Ethical approval was obtained from the Ethics Committee of Sichuan Provincial People’s Hospital (approval number: 2021 No. 413–1). Informed consent forms were signed voluntarily by each participant, indicating their understanding and agreement to participate in the study. Participants flow chart. Inclusion Criteria (1) Patients with COPD confirmed by pulmonary function testing, excluding other conditions that could cause similar symptoms and persistent airflow limitation. (2) Patients with stable COPD diagnosed according to the criteria outlined in the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) 2021 guidelines.16 (3) Patients with available pulmonary function test results obtained within one month. Exclusion Criteria (1) Individuals with confirmed diagnoses of other diseases or characteristic pathological or radiological features of airflow limitation, such as obstructive pneumonia, pleural effusion, pulmonary tuberculosis, diffuse panbronchiolitis, restrictive ventilatory dysfunction, etc. (2) Limited lower limb mobility, limb amputation, prosthetic limbs, unwillingness to participate, or inability to complete the measurements. (3) Coexistence of severe active lesions in the cardiovascular, cerebral, hepatic, renal, neuromuscular, and metabolic systems, or advanced stages of malignant tumors. (4) The diagnosis of a disease in the exclusion criteria was determined by medical records, clinical history, chest imaging, and laboratory findings. Pulmonary Function Tests Spirometry was used to quantify the FVC, FEV1, FEV1/FVC, FEV1/VC, and FEV1%pred (Master Sereen, Germany). The tests were performed by physicians in the pulmonary function room of Sichuan Provincial People’s Hospital according to the American Thoracic Society and European Respiratory Society.17 Measurement of Muscle Strength and Function Muscle strength was assessed by measuring grip strength, and muscle function was assessed by six-meter walk test (6MWT) and five-repetition sit-to-stand (5STS) test. Grip strength was measured using a handheld electronic handgrip dynamometer (Campy, China). Each hands were measured twice, and the result was taken as the maximum of the four values, accurate to 0.01kg. According to the sarcopenia consensus,8 a 6MWT was used to measure gait speed. Measurements were made twice and the average was recorded to an accuracy of 0.01 m/s. The time taken by the patient to complete 5STS tests was recorded, and the average of the two measurements was taken, accurate to 0.01 seconds. Measurement of Muscle Mass Through BIA with the Inbody 770 device (Inbody, Korea), measurements of weight and appendicular skeletal muscle mass (ASM) were taken to calculate the appendicular skeletal muscle index (ASMI). Muscle mass was also assessed using US examination.15 Lower limb muscle mass parameters, including RFCSA, FMT, and QFMT, were measured by the same experienced ultrasonographer using an US system (Samsung RS80A, Korea) with a 3–12 MHz linear array transducer. US measurements were performed with the patient supine, both lower limbs extended and relaxed. The right lower limb was examined. A generous layer of coupling gel was applied, and the transducer was placed perpendicular to the skin with minimal compression to avoid tissue deformation. Measurements were taken at the midpoint between the anterior inferior iliac spine and the proximal patellar border. FMT (superficial to deep fascia of rectus femoris), QFMT (superficial fascia of rectus femoris to femoral cortex), and RFCSA (manual tracing with automatic area calculation) were measured three times and averaged (Figure 2). The intra-observer intraclass correlation coefficients (ICCs) were 0.92, 0.91, and 0.90, respectively (95% CIs: 0.88–0.95, 0.87–0.95, 0.85–0.94). Illustration of US measurements of lower limb muscles. Abbreviations: VL, Vastus lateralis muscle; RFM, Rectus femoris muscle; VM, Vastus medialis muscle; VI, Vastus intermedius muscle. The blue arrows indicate muscle thickness measurements, including FMT and QFMT. The blue dotted circle represents the outlined RFCSA. Sarcopenia Definition This study adopted the diagnostic criteria for sarcopenia according to AWGS 2019:8 (1) Muscle strength: grip strength <28 kg for men, <18 kg for women. (2) Physical function: gait speed <1.0 m/s over 6 m, or sit-to-stand time ≥12 s for 5 repetitions. (3) Muscle mass: Estimated using the reference index ASMI: <7.0 kg/m2 for men, < 5.7 kg/m2 for women using BIA. Sarcopenia was diagnosed when low muscle mass was present in combination with low muscle strength and/or low physical function. Those who did not meet these combined criteria were classified as non-sarcopenia. Cases of “possible sarcopenia” were excluded from the sarcopenia group. Statistical Analysis The data were analyzed using IBM SPSS 27.0, MedCalc 22.0, and GraphPad Prism 9.0 software. Normally distributed continuous variables were reported as mean ± standard deviation, and between-group comparisons were conducted using independent samples t-test. Non-normally distributed continuous variables and count data were presented as median (interquartile range), and between-group comparisons were performed using the Mann–Whitney U-test. Receiver operating characteristic curves (ROC) were used to evaluate the screening utility of lower limb muscles in COPD with sarcopenia. Multivariate confounders were analyzed with the use of binary logistic regression. Statistical significance was set at p<0.05. Results Characteristics of Clinical Demographic Data The proportion of participants with sarcopenia in this cohort was 39.34% (24/61). No significant differences were observed between the sarcopenic and non-sarcopenic groups in age (74 vs 71 years, p=0.052), COPD duration (4 vs 2 years, p=0.064), CAT score (13 vs 12, p=0.068), or smoking status (p=0.674). However, the sarcopenic group had significantly lower height (157.50±9.49 cm vs 162.62±7.82 cm, p=0.025), weight (51.26±8.48 kg vs 60.93±10.21 kg, p<0.001), and BMI (20.67±2.99 kg/m2 vs 23.08±3.82 kg/m2, p=0.011) compared to the non-sarcopenic group. Additionally, the sarcopenic group exhibited a significantly higher mMRC score (2 vs 1, p=0.044) (Table 1). Table 1Analysis of Clinical Characteristics Data Between Non-Sarcopenic and Sarcopenic GroupsVariableNon-Sarcopenic(n=37)Sarcopenic(n=24)Total(n=61)P valueAge (years)71(63–86)74(64–91)73(63–91)0.052Gender0.854 Male30(81.1%)19(79.2%)49(80.3%) Female7(18.9%)5(20.8%)12(19.7%)Height (cm)162.62 ± 7.82157.50 ± 9.49160.61 ± 8.810.025*Weight (kg)60.93 ± 10.2151.26 ± 8.4857.12 ± 10.62<0.001***BMI (kg/m 2)23.08 ± 3.8220.67 ± 2.9922.13 ± 3.690.011*COPD duration (year)2(1–20)4(1–10)3(1–20)0.064mMRC score1(0–3)2(1–4)1(0–4)0.044*CAT score12(5–26)13(9–21)12(5–26)0.068Smoking status0.674 Non-smoker9(24.3%)7(29.2%)16(26.2%) Smoker28(75.7%)17(70.8%)45(73.8%)Notes: *p < 0.05, ***p < 0.001.Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; mMRC, modified Medical Research Council; CAT, COPD Assessment Test. Analysis of Clinical Characteristics Data Between Non-Sarcopenic and Sarcopenic Groups Notes: *p < 0.05, ***p < 0.001. Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; mMRC, modified Medical Research Council; CAT, COPD Assessment Test. Results of Measured Parameters in Sarcopenic and Non-Sarcopenic Groups About muscle strength, function and quality, all parameters except body fat mass (BFM) and fat percentage differed significantly between groups (p<0.001). Compared to non-sarcopenic patients, those with sarcopenia had slower gait speed (1.00 m/s vs 1.22 m/s), longer 5STS time (11.06±2.04 s vs 9.06±1.52 s), and lower grip strength (23.99±6.09 kg vs 31.71±6.93 kg) (all p<0.001). Muscle mass parameters, including appendicular skeletal muscle mass (ASM), ASMI, body skeletal muscle mass (BSM), and calf circumference (CC), were also significantly reduced in the sarcopenic group (all p<0.001). No significant differences were observed in BFM (p=0.057) or fat percentage (p=0.705) (Table 2). Table 2Measurement Values for Sarcopenia Diagnosis and Pulmonary Function Across GroupsVariableNon-Sarcopenic(n=37)Sarcopenic(n=24)Total(n=61)P valueMuscle strength and function Gait speed (m/s)1.22(0.79–1.56)1.00(0.81–1.57)1.15(0.79–1.57)<0.001*** 5STS (seconds)9.06 ± 1.5211.06 ± 2.049.83 ± 1.98<0.001*** Grip strength (kg)31.71 ± 6.9323.99 ± 6.0928.67 ± 7.58<0.001***Muscle mass ASM (kg)18.35 ± 3.2914.86 ± 3.3016.98 ± 3.69<0.001*** ASMI (kg/m2)6.89 ± 0.725.90 ± 0.716.50 ± 0.88<0.001*** BSM (kg)24.17 ± 3.8620.50 ± 3.7722.73 ± 4.20<0.001*** BFM (kg)16.46 ± 7.9013.10 ± 5.6115.13 ± 7.230.057 Fat percentage (%)26.05 ± 10.3925.06 ± 8.9825.66 ± 9.800.705 CC (cm)35.93 ± 2.6332.48 ± 2.0334.57 ± 2.94<0.001***Pulmonary function FEV1 (L)1.31(0.67–2.91)1.05(0.48–2.49)1.17(0.48–2.91)0.011* FVC (L)2.57 ± 0.752.07 ± 0.692.37 ± 0.770.012* FEV1/FVC (%)55.87 ± 9.3153.47 ± 10.6354.93 ± 9.840.355 FEV1/VC (%)52.71 ± 10.1950.39 ± 10.9451.80 ± 10.460.401US parameters FMT (cm)1.43 ± 0.231.30 ± 0.211.38 ± 0.230.033* RFCSA (cm2)4.72 ± 0.754.25 ± 0.754.54 ± 0.780.019* QFMT(cm)2.57(2.00–4.27)2.28(1.37–2.83)2.43(1.37–4.27)<0.001***Notes: *p < 0.05, ***p < 0.001.Abbreviations: 5STS, five-repetition sit-to-stand test; ASM, appendicular skeletal muscle mass; ASMI, appendicular skeletal muscle mass index; BSM, body skeletal muscle mass; BFM, body fat mass; CC, calf circumference; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; VC, vital capacity; US, Ultrasound; FMT, femoral muscle thickness; RFCSA, rectus femoris cross-sectional area; QFMT, quadriceps femoris muscle thickness. Measurement Values for Sarcopenia Diagnosis and Pulmonary Function Across Groups Notes: *p < 0.05, ***p < 0.001. Abbreviations: 5STS, five-repetition sit-to-stand test; ASM, appendicular skeletal muscle mass; ASMI, appendicular skeletal muscle mass index; BSM, body skeletal muscle mass; BFM, body fat mass; CC, calf circumference; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; VC, vital capacity; US, Ultrasound; FMT, femoral muscle thickness; RFCSA, rectus femoris cross-sectional area; QFMT, quadriceps femoris muscle thickness. Patients with sarcopenia demonstrated significantly lower FEV1 (1.05 L vs 1.31 L, p=0.011) and FVC (2.07±0.69 L vs 2.57±0.75 L, p=0.012) compared to non-sarcopenia patients. All measured lower limb muscle parameters were significantly reduced in the sarcopenic group. Specifically, patients with sarcopenia had lower FMT (1.30±0.21 cm vs 1.43±0.23 cm, p=0.033), smaller RFCSA (4.25±0.75 cm2 vs 4.72±0.75 cm2, p=0.019), and QFMT (2.28 cm vs 2.57 cm, p<0.001) compared to non-sarcopenic patients (Figure 3). Comparison of lower limb muscles between sarcopenia and non-sarcopenia groups. Notes: *p < 0.05, ***p < 0.001. Abbreviations: Sar, Sarcopenic; Non-Sar, Non-Sarcopenic; FMT, femoral muscle thickness; RFCSA, rectus femoris cross-sectional area; QFMT, quadriceps femoris muscle thickness. Screening Efficacy of Muscle Parameters for Sarcopenia Figure 4 shows the diagnostic efficacy of ROC curve analysis of lower limb muscle parameters for COPD with sarcopenia. The combined diagnostic model was established using binary logistic regression including QFMT, FMT, and RFCSA. The AUC values were: QFMT 0.767 (95% CI: 0.642–0.866), FMT 0.666 (95% CI: 0.534–0.782), and RFCSA 0.648 (95% CI: 0.515–0.766). When they were combined, the AUC was 0.777 (95% CI: 0.652–0.874) (Table 3). The combined model using the DeLong test showed no statistically significant difference (p=0.711), indicating that the incremental value of the combined model over QFMT alone is marginal. ROC curve of lower limb muscle parameters for the diagnosis of sarcopenia. Abbreviations: AUC, area under curve; FMT, femoral muscle thickness; RFCSA, rectus femoris cross-sectional area; QFMT, quadriceps femoris muscle thickness; Combination, Combined predictive values of FMT, RFCSA, and QFMT. Table 3Sensitivity and Specificity of Lower Limb Muscle Parameters in the Diagnosis of SarcopeniaVariableAUCSensitivitySpecificityYouden IndexCut-Off Value(Predicted Probability)95% CICombination0.77750.00%94.59%0.44590.5730.652–0.874QFMT0.767100.00%43.24%0.43242.8330.642–0.866FMT0.66666.67%67.57%0.34231.310.534–0.782RFCSA0.64895.83%32.43%0.28275.170.515–0.766Abbreviations: FMT, femoral muscle thickness; RFCSA, rectus femoris cross-sectional area; QFMT, quadriceps femoris muscle thickness; Combination, Combined predictive values of FMT, RFCSA, and QFMT; CI, confidence interval; AUC, Area under curve. Sensitivity and Specificity of Lower Limb Muscle Parameters in the Diagnosis of Sarcopenia Abbreviations: FMT, femoral muscle thickness; RFCSA, rectus femoris cross-sectional area; QFMT, quadriceps femoris muscle thickness; Combination, Combined predictive values of FMT, RFCSA, and QFMT; CI, confidence interval; AUC, Area under curve. The sensitivity and specificity at the optimal cut-offs (determined by the Youden index) are presented in Table 3. QFMT (sensitivity 100%, specificity 43.24%) and RFCSA (sensitivity 95.83%, specificity 32.43%) behaved as screening tests, whereas the combined model (sensitivity 50%, specificity 94.59%) behaved as a confirmatory test. Multivariable Logistic Regression Analysis To determine whether QFMT remained an independent predictor of sarcopenia after adjusting for potential confounders, we performed multivariable logistic regression analysis including age, sex, BMI, and FEV1%pred as covariates. As shown in Table 4, QFMT was the only independent predictor of sarcopenia in this COPD cohort (OR = 0.121, 95% CI: 0.021–0.697, p = 0.018). Neither age, sex, BMI, nor FEV1%pred showed statistically significant associations with sarcopenia in the adjusted model (all p > 0.05). Table 4Multivariable Logistic Regression Analysis ResultsVariableBSEWald χ2P valueOR (95% CI)QFMT (cm)−2.1130.8945.5860.018*0.121 (0.021–0.697)Age (years)0.1100.0573.6970.0551.116 (0.998–1.248)Sex (male vs female)0.2660.9300.0820.7751.305 (0.211–8.069)BMI (kg/m2)−0.1670.1082.3820.1230.846 (0.685–1.046)FEV1pred (%)−0.0120.0170.4930.4820.988 (0.957–1.021)Note: *p < 0.05.Abbreviations: SE, standard error; OR, odds ratio; CI, confidence interval; QFMT, quadriceps femoris muscle thickness; BMI, body mass index; FEV1%pred, percentage of predicted forced expiratory volume in one second. Multivariable Logistic Regression Analysis Results Note: *p < 0.05. Abbreviations: SE, standard error; OR, odds ratio; CI, confidence interval; QFMT, quadriceps femoris muscle thickness; BMI, body mass index; FEV1%pred, percentage of predicted forced expiratory volume in one second. Discussion This cross-sectional study was designed to investigate screening utility of lower limb muscle US parameters, namely QFMT, FMT, and RFCSA, for COPD patients with sarcopenia. Our study found that US parameters show promise as screening tools for COPD with sarcopenia. In this study, 61 COPD patients were included, and the proportion of participants with sarcopenia was 39.34% (24/61). This result is higher than the overall proportion of COPD with sarcopenia (21.6%) reported in the meta-analysis published by Benz et al18 and higher than the 29% reported by Yu et al.5 However, the older age of the study population (median age in this study was 73 years), the diagnostic criteria of sarcopenia used in different studies (AWGS 2019 was used in this study8), and regional ethnic differences may contribute to the different proportions. Sepulveda-Loyola et al19 also pointed out that the proportion of COPD with sarcopenia fluctuated between 15.5% and 41.0% depending on the diagnostic criteria, disease severity, and treatment setting, and the results of this study were within this range. Notably, the mMRC score of the sarcopenia group in this study was higher than that of the non-sarcopenia group (p=0.044), suggesting that sarcopenia may exacerbate dyspnea symptoms in COPD patients, and this finding is consistent with the study conclusion of Jones et al.20 There were significant differences in weight and BMI between the two groups (p < 0.05), suggesting that nutritional status was also closely related to COPD with sarcopenia. However, the difference of individual height should be carefully interpreted, which is unlikely to have significant clinical significance, and may be caused by a small sample size. Our findings share similarities with recent US studies in non-COPD populations. Staempfli et al14 reported that rectus femoris was the most reliable parameter for assessing muscle mass in community-dwelling older adults, with excellent reproducibility. At the same time, they also pointed out that more added value could be obtained by analyzing qualitative muscle parameters (such as echo intensity) of US in the diagnosis of sarcopenia in the elderly.14 A systematic review and meta-analysis by Fu et al21 also suggested that US measurements of the rectus femoris and quadriceps femoris may be useful for sarcopenia screening. These observations, together with our results in patients with COPD, support the broader applicability of lower limb muscle US as a screening tool in diverse patient populations. To examine whether US parameters are independent predictors of sarcopenia after adjusting for confounders, we also performed multivariable logistic regression including age, sex, BMI, and FEV1%pred. The results showed that QFMT remained an independent predictor of sarcopenia (adjusted OR = 0.121, 95% CI: 0.021–0.697, p = 0.018). In this study, FEV1 and FVC were significantly lower in the sarcopenia group than in the non-sarcopenia group (p<0.05), but there were no significant differences in FEV1%pred and FEV1/FVC between the two groups. This result is similar to that reported by Choi et al,2 which showed a faster rate of decline in lung function in COPD patients with sarcopenia, but no significant difference in FEV1 (%) pred. Moreover, a prospective study by Wu et al3 reported that sarcopenia increased the risk of acute exacerbations in elderly COPD patients, while FEV₁ was also found to be associated with sarcopenia incidence. The latest study published by Yang et al22 pointed out that the correlation between lung function and sarcopenia in COPD patients may be influenced by mediating factors such as inflammatory response and low physical activity. This suggests that sarcopenia may mainly affect the absolute values of lung function (FEV1 and FVC), rather than the indicators of airway obstruction. The reason for this result may be that respiratory muscle, as a part of skeletal muscle, is involved in the pathological process of sarcopenia. The rectus femoris is a pivotal player in the regulation of gait and mobility; the accessibility of the rectus femoris is favorable for point-of-care US assessment. In this study, it was found that the FMT of COPD patients with sarcopenia was significantly reduced, and the results of a systematic review analysis by Staempfli et al were similar.14 Their analysis pointed out that for the validity of muscle US in sarcopenia assessment, FMT was the most reliable and reproducible parameter for assessing muscle mass.14 In addition, we also found that QFMT and RFCSA showed screening utility in the assessment of COPD with sarcopenia, with AUC values of 0.767 and 0.648. This is consistent with the recent findings of Huang et al23 in elderly COPD patients, which adds more clinical evidence for the use of lower limb muscle US in COPD with sarcopenia. Interestingly, Perkisas et al15 also emphasized in SARCUS update consensus that lower limb muscle US is gradually becoming an effective supplement to traditional muscle mass assessment methods such as DXA and CT due to its advantages of no radiation, portability and low-cost. It is noteworthy that QFMT showed the most significant between-group difference in this study (p<0.001) and the best single diagnostic efficacy in ROC analysis (AUC=0.767). As the largest knee extensor muscle group of the lower limbs, the quadriceps femoris plays a pivotal role in maintaining the daily activities of COPD patients such as standing, walking, and going up and down stairs.13 As early as 2010, Seymour et al24 reported that the prevalence of quadriceps weakness in COPD patients was 33.3%, which was closely associated with disease severity and exercise tolerance. Subsequently, Shrikrishna et al25 further confirmed that quadriceps wasting and reduced physical activity levels in COPD patients are bidirectionally related, creating a vicious cycle. Therefore, as an indicator for identifying COPD with sarcopenia, QFMT may better reflect the functional reserve of the lower limbs compared to other muscles such as the rectus femoris. Interestingly, the combination of QFMT, FMT, and RFCSA for identifying COPD with sarcopenia yielded an AUC of 0.777, slightly higher than QFMT alone (AUC 0.767). However, the DeLong test showed no statistically significant difference between the combined model and QFMT alone (p=0.711). This suggests that multi-parameter US assessment may provide marginal improvement in screening performance, but QFMT alone may be sufficient as an initial screening tool. A systematic review and meta-analysis on the accuracy of US for sarcopenia diagnosis also indicated that the combined diagnostic efficiency of multi-muscle US parameters may be superior to single parameters.21 In our study, the sensitivity of QFMT was higher than that reported by Fu et al21(100% vs 63%), but the specificity was lower (43.24% vs 77%). A potential two-step screening strategy—initial screening with QFMT at a cut-off of 2.833 cm to maximize sensitivity, followed by diagnosis using the combined model to ensure high specificity—is reasonable as a hypothesis. However, this strategy was derived and tested in the same small sample and requires prospective validation before clinical application. This study has several limitations. First, the relatively small sample size (n=61) and single-center design may limit the generalizability of the findings and introduce selection bias, warranting validation through larger, multicenter studies in the future. The limited number of sarcopenia cases (n=24) also raises the risk of overfitting in the combined diagnostic model, which we attempted to address through bootstrap internal validation. Second, the cross-sectional design precludes the assessment of the prognostic value of these parameters for longitudinal outcomes, such as acute exacerbations, rehospitalization, or mortality. Third, muscle mass was assessed by BIA rather than the gold-standard DXA or CT; therefore, the US parameters were validated against a BIA-derived reference standard, and external validation against DXA/CT is lacking. Fourth, this study only measured muscle thickness and cross-sectional area in the lower limbs, omitting US echo intensity, which may affect the accuracy of the diagnostic model. Fifth, all US measurements were performed by a single experienced sonographer; although the intra-observer reliability was excellent, the operator-dependency of US limits its generalizability to settings with less experienced operators. We plan to address these limitations in our subsequent research. Future research will work to address these limitations and provide more comprehensive insights. Conclusion In conclusion, this study demonstrates that lower limb muscle US parameters (QFMT, FMT, and RFCSA) are significantly reduced in COPD patients with sarcopenia. Among them, QFMT showed promise as a single screening parameter. US appears promising as a non-invasive, convenient, and cost-effective screening tool for the identification of sarcopenia in COPD patients; however, these findings require validation in larger, prospective, multicenter studies using established reference standards such as DXA or CT. Acknowledgments The authors would like to thank the patients and the teachers of the Department of Ultrasound Medicine of Sichuan Provincial People’s Hospital for their guidance. Funding Statement This work was supported by the Nanchong Federation of Social Science Circles (NC26C439) and the Health Science Research Project of Sichuan Province (Chuan Gan Yan ZH2021-201). Data Sharing Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. Ethics Approval and Consent to Participate The study was approved by the Ethics Committee of Sichuan Provincial People’s Hospital (registration number: 2021 No. 413-1). The study abides by principles in the Declaration of Helsinki for the use of human samples. Signed informed consent was obtained from all patients. Author Contributions All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure The authors report no conflicts of interest in this work. References Associated Data Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.